OPTH · Optimi Health Corp.

Summary

Optimi Health Corp. is a Canadian GMP-compliant pharmaceutical drug manufacturer licensed by Health Canada for handling controlled substances, specializing in MDMA and botanical psilocybin products from two 10,000-square-foot facilities in Princeton, British Columbia. Operating under a Drug Establishment Licence (DEL) and Dealer’s Licence (DL), the company supplies prescription MDMA for PTSD and psilocybin for treatment-resistant depression (TRD) in Australia via the Authorised Prescribers Scheme, and supports clinical trials in Canada and Israel. Financially, it reported revenue of C$426,301 for FY2025 (up from C$389,850 in FY2024) but incurred a net loss of C$3.7 million with accumulated deficit of C$27.2 million and cash of C$1.1 million as of September 30, 2025. The company is pursuing a Nasdaq uplisting under 'OPTH' via this F-1/A filing dated February 17, 2026, with a planned reverse share split to meet minimum price requirements. Net proceeds, estimated at US$ million from the midpoint price, will fund production scaling in current markets, market expansion to Israel and the US, sales growth, and working capital. As an emerging growth company and foreign private issuer, Optimi leverages regulatory approvals and vertical integration for competitive advantages in the nascent psychedelic therapeutics sector, positioning for growth amid evolving global regulations.

Key takeaways

• Canadian GMP-compliant manufacturer of MDMA and psilocybin with DEL awarded May 2024, enabling exports to Australia where products are prescribed for PTSD and TRD.
• FY2025 revenue C$426k (71% from drug products/licensing), net loss C$3.7M, cash C$1.1M, accumulated deficit C$27.2M as of September 30, 2025.
• Two 10,000 sq ft facilities in Princeton, BC; DL allows possession of up to 20kg psilocybin, 200g psilocin, 2kg MDMA.
• Net proceeds ~US$ million for scaling production/distribution, US/Israel expansion, sales growth, working capital; Nasdaq uplisting under OPTH planned.
• Key risks: regulatory compliance for controlled substances, limited operating history with recurring losses, dependence on license maintenance, US Schedule I restrictions.
• No patents; relies on proprietary know-how/trade secrets; FY2025 current liabilities C$8.5M exceed current assets C$1.8M.